References

Cure Arthritis Naturally

Beat Arthritis Naturally

Get Instant Access

Abbott Laboratories (2006) Adalimumab [prescribing information]. Abbott Laboratories, North Chicago, IL Anderson PJ (2005) Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles. Semin Arthritis Rheum 34(5 Suppl1):19-22 Baert F, Noman M, Vermeire S, et al. (2003) Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 348:601 -608 Barrera P, Joosten LA, Den Broeder AA, et al. (2001) Effects of treatment with a fully human anti-tumour necrosis factor a monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFa in patients with rheumatoid arthritis. Ann Rheum Dis 60:660-669

Bieber J, Kavanaugh A (2004) Consideration of the risk and treatment of TB in patients with rheumatoid arthritis receiving biologic treatments. Rheum Dis Clin North Am 30: 257-270

Braegger CP, Nicholls S, Murch SH, Stephens S, MacDonald TT (1992) Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 339:89-91 Braun J, Bollow M, Neure L, et al. (1995) Use of immunohisto-logic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 38:499-505 Braun J, Brandt J, Listing J, et al. (2002) Treatment of active ankylosing spondylitis with infliximab: a randomized controlled multicentre trial. Lancet 359:1187-1193 Breedveld FC, Weisman MH, Kavanaugh AF, et al. (2005) The efficacy and safety of adalimumab (Humira®) plus methotrexate vs. adalimumab alone or methotrexate alone in the early treatment of rheumatoid arthritis: 1- and 2-year results of the PREMIER study [abstract]. Ann Rheum Dis 64 (Suppl III):60 (0P013)

Breedveld FC, Weisman MH, Kavanaugh AF, et al., for the PREMIER investigators (2006) The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus metho-trexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54:26-37 Brenner DA, O'Hara M, Angel P, Chojkier M, Karin M (1989) Prolonged activation of jun and collagenases genes by tumour necrosis factor-alpha. Nature 337:661 -663 Burmester GR, van de Putte LBA, Rau R, Schattenkirchner M, Hartz D, Kupper H (2003) Sustained efficacy of adalimumab monotherapy for more than four years in DMARD-refracto-ry RA [abstract]. Ann Rheum Dis 62(Suppl 1):192-193 (Poster THU0275) Burmester GR, Saez IM, Malaise M, et al. (2004) Efficacy and safety of adalimumab in European clinical practice: the ReAct Trial [abstract]. Ann Rheum Dis 63(Suppl 1):90 (0P0105)

Burmester GR, Monteagudo Säez I, Malaise MG, Kary S, Kupper H (2005) Adalimumab (Humira®) is effective and safe in treating rheumatoid arthritis (RA) in real-life clinical practice: 1-year results of the ReAct study [abstract]. Arthritis Rheum 52(Suppl):S541-S542 (poster 1436) Catrina AI, Trollmo C, af Klint E, et al. (2005) Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report. Arthritis Rheum 52:61-72 Cooper W0, Fava RA, Gates CA, Cremer MA, Townes AS (1992) Acceleration of onset of collagen-induced arthritis by intra-articular injection of tumour necrosis factor or transforming growth factor-beta. Clin Exp Immunol 89:244-250 Furst DE, Schiff MH, Fleischmann RM, et al. (2003) Efficacy and safety of the fully human anti-tumour necrosis factor-a monoclonal antibody, and concomitant standard antirheu-matic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 30:2563-2571

Genovese MC, Mease PJ, Thomson GT, Kivitz AJ, Perdok RJ, Weinberg MA (2005) Adalimumab efficacy in patients with psoriatic arthritis who failed prior DMARD therapy [abstract]. Ann Rheum Dis 64 (Suppl III [3]):313 (poster FRI0187)

Georgopoulos S, Plows D, Kollias G (1996) Transmembrane TNF is sufficient to induce localized tissue toxicity and chronic inflammatory arthritis in transgenic mice. J Inflamm 46:86-97 Granneman RG, Zhang Y, Noetersheuser PA, et al. (2003) Pharmacokinetic/pharmacodynamic (PK/PD) relationships of adalimumab (Humira™, Abbott) in rheumatoid arthritis patients during Phase II/III clinical trials [abstract]. Arthritis Rheum 48(Suppl):S140 (poster 256) Gridley G, McLaughlin JK, Ekbom A, et al. (1993) Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 85:307-311 Hanauer SB, Sandborn WJ, Rutgeerts P, et al. (2006) Human anti-tumor necrosis factor monoclonal antibody (adalimu-mab) in Crohn's disease: the CLASSIC-I Trial. Gastroenter-ology (in press) Heinzlef O, Alamowitch S, Sazdovitch V, et al. (2000) Autoimmune diseases in families of French patients with multiple sclerosis. ActaNeurol Scand 101:36-40 Isomaki HA, Hakulinen T, Joutsenlahti U (1978) Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis. J Chronic Dis 31:691-696 Jerne NK (1974) Towards a network theory of the immune system. Ann d'Immunologie 125C:373-389 Kavanaugh A, Grenwald M, Zizic T, et al. (2002) Treatment with adalimumab (D2E7) does not affect normal immune responsiveness [abstract]. Arthritis Rheum 45(Suppl 9):S132 Kavanaugh A, Cush JJ, Matteson E, ACR Hotline (2003) FDA meeting March 2003: update on the safety of new drugs for rheumatoid arthritis. Part II. CHF, infection, and other safety issues. Available at: http://www.rheumatology.org/publi-cations/hotline/0803chf.asp?aud=mem. Accessed September 11,2006

Kaymakcalan Z, Beam C, Kamen R, Salfeld J (2002) Comparison of adalimumab (D2E7), infliximab, and etanercept in the prevention ofpolyarthritis in a transgenic murine model of rheumatoid arthritis. Arthritis Rheum 46(Suppl):S304 Keystone E, Furst DE, Kavanaugh AF, Chartash E, Fischkoff S (2003a) Subgroup analysis of radiographic progression in RA patients treated with adalimumab [abstract]. Ann Rheum Dis 62(Suppl 1):169 (poster THU0198) Keystone E, Kavanaugh AF, Fischkoff S, et al. (2003b) Response to adalimumab in patients with early versus late rheumatoid arthritis (RA) [abstract]. Ann Rheum Dis 62(Suppl 1):170 (poster THU0201) Keystone E, Haraoui B, Bykerk VP (2003c) Role of adalimumab in patients with early versus late rheumatoid arthritis (RA) [abstract]. Clin Exp Rheumatol 21(5 Suppl 31):S198-S199 Keystone ED, Kavanaugh AF, Sharp JT, et al. (2004a) Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy. Arthritis Rheum 50:1400-1411

Keystone ED, Kavanaugh AF, Sharp JT, et al. (2004b) Inhibition of structural damage sustained in patients with long-standing rheumatoid arthritis following 3 years of treatment with adalimumab (HUMIRA) plus methotrexate [abstract]. Arthritis Rheum 50(Suppl):S189 (poster 370) Keystone EC, Kavanaugh AF, Sharp JT, et al. (2005) Inhibition of radiographic disease progression in patients with longstanding rheumatoid arthritis following 3 years oftreatment with adalimumab (Humira®) plus methotrexate. Ann Rheum Dis (Suppl III):419 (poster SAT0034) Kristensen L, Saxne T, Geborek P (2004) Adherence to therapy of infliximab, etanercept, adalimumab, and anakinra in chronic arthritis patients treated in clinical practice in southern Sweden [abstract]. Ann Rheum Dis 64(Suppl 1):263 (poster FRI0049) Langley R, Leonardi C, Toth D, et al. (2005) Long-term safety and efficacy of adalimumab in the treatment of moderate to severe chronic plaque psoriasis [abstract]. J Am Acad Der-matol 52(3 Suppl)203 (poster P2825) Lee SJ, Kavanaugh A (2005) Adalimumab for the treatment of rheumatoid arthritis. Therapy 2:13-21 Leonardi CL, Powers JL, Matheson RT, et al., for the Etanercept Psoriasis Study Group (2003) Etanercept as monotherapy in patients with psoriasis. N Engl J Med 349:2014 - 2022 Lovell D, Giannini, E, Reiff A, et al. (2000) Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 342:763-769 Lovell DJ, Ruperto N, Goodman S, et al. (2004) Preliminary data from the study ofadalimumab in children with juvenile idiopathic arthritis (JIA). Arthritis Rheum 50(Suppl):S436-S437

Magnano M, Robinson WH, Genovese MC (2004) Demyelin-ation and the use of TNF inhibition. Clin Exp Rheumatol 22(5 Suppl 35):S134-S140 Maini RN, Breedveld FC, Kalden JR, et al. (1998) Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41:1552-1563 Mease P (2002) Tumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors. Ann Rheum Dis 61:298-304 Mease P (2005) TNF-a inhibitors in psoriatic arthritis. In: Gordon KB, Ruderman EM (eds) Psoriasis and psoriatic arthritis: an integrated approach. Springer-Verlag, Heidelberg, pp 223-234

Mease PJ, Gladman DD, Ritchlin CT, et al., for the ADEPT Study Group (2005a) Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. ADEPT. Arthritis Rheum 52:3279-3289 Mease PJ, Gladman DD, Ritchlin CT, et al. (2005b) Clinical efficacy and safety of adalimumab for psoriatic arthritis: 48-week results of ADEPT [abstract]. Arthritis Rheum 52(Suppl):S215 (Poster 500) Mease P, Sharp J, Ory P, et al. (2005c) Inhibition of joint destruction in PsA with adalimumab: 48-week results of ADEPT [abstract]. Arthritis Rheum 52(Suppl):S631 (poster 1699)

Mellemkjaer L, Linet MS, Gridley G, Frisch M, Moller H, Olsen JH (1996) Rheumatoid arthritis and cancer risk. Eur J Cancer 32A:1753 -1757 Menter MA, Gordon K, Leonardi C, Chen D (2005) Adalimumab efficacy and safety results in patients with moderate to severe chronic plaque psoriasis with and without psoriatic arthritis [abstract]. J Am Acad Dermatol 52(3 Suppl):174 (poster P2713)

Mitoma H, Horiuchi T, HattaN, et al. (2005) Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-[945]. Gastroenterology 128:376-392 Murch SH, Lamkin VA, Savage MO, Walker-Smith JA, MacDonald TT (1991) Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut 32:913-917 Murch SH, Braegger CP, Walker-Smith JA, MacDonald TT (1993) Location of tumour necrosis factor alpha by immu-nohistochemistry in chronic inflammatory bowel disease. Gut 34:1705-1709 O'Dell J (2002) Treating rheumatoid arthritis early: a window of opportunity? Arthritis Rheum 46:283-285 Papadakis KA, Targan SR (2000) Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology 119:1148-1157 Partsch G, Steiner G, Leeb BF, Dunky A, Broll H, Smolen JS (1997) Highly increased levels of tumor necrosis factor-a and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol 24:518-523 Paulson SK, Noertersheuser P, Pollack P, Hoffman R (2005) Pharmacokinetics of adalimumab from CLASSIC, a randomized phase 3 trial for the induction of clinical remission in patients with Crohn's disease [abstract]. Gastroenterology 128(4 Suppl 2):A-585 (poster W1057) Ritchlin C, Haas-Smith SA, Hicks D, Cappuccio J, Osterland CK, Looney RJ (1998) Patterns of cytokine production in psoriatic synovium. J Rheumatol 25:1544-1552 Salfeld J, Kaymakcalan Z, Tracey D, Robert A, Kamen R (1998) Generation of fully human anti-TNF antibody D2E7 [abstract]. Arthritis Rheum 41(Suppl):S57 Sandborn W, Hanauer S, Lukas M, et al. (2005a) Induction and maintenance of clinical remission and response in subjects with Crohn's disease treated during a 6-month open-label period with fully human anti-TNF- monoclonal antibody adalimumab (Humira®). Gastroenterology 128(4 Suppl 2):A-111 (presentation 723) Sandborn WJ, Hanauer S, Enns R, et al. (2005b) Maintenance of remission over 1 year in patients with active Crohn's disease treated with adalimumab: results of CLASSIC II, a blinded, placebo-controlled study. Gut 54(Suppl VII):A81 -2 (oral presentation OP-G-353) Sandborn WJ, Hanauer S, Lukas M, et al. (2005c) Clinical remission and response in patients with Crohn's disease treated with open-label for 1 year with fully human anti-TNF- monoclonal antibody adalimumab. Gut 54(Suppl VII):A18 (oral presentation OP-G-78) Saxne T, Palladino MA Jr, Heinegard D, Talal N, Wollheim FA (1988) Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum 31:1041 -1045

Scallon BJ, Moore MA, Trinh H, Knigh DM, Ghrayeb J (1995) Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 7:251-259 Schiff M, van de Putte LB, Breedveld FC, et al. (2003) Rates of infection in adalimumab rheumatoid arthritis clinical trials [abstract]. Ann Rheum Dis 62(Suppl I):184 (poster THU0246)

Schiff MH, Burmester GR, Kent J, et al. (2005) Safety of adalimumab in long-term treatment of patients with rheumatoid arthritis [abstract]. J Am Acad Dermatol 52(3 Suppl):203 (poster P2826)

Schiff MH, Burmester GR, Kent J, et al. (2006) Safety analyses of adalimumab (HUMIRA®) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 65:889-894 Shen C, Assche GV, Colpaert S, et al. (2005) Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment Pharmacol Ther 21(3):251 -258 van den Brande JM, Braat H, van den Brink GR, et al. (2003) Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 124:1774-1785 van der Heijde D, Dijkmans B, Geusens P, et al., for the Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group (2005) Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 52:582-591 van der Heijde D, Kivitz A, Schiff MH, et al. (2006) Efficacy and safety of adalimumab in patients with ankylosing spondyli-tis: results of a randomized, placebo-controlled trial (ATLAS). Arthritis Rheum 54:2136-2146 van de Putte LBA, Salfeld J, Kaymakcalan Z (2003) Adalimumab. In: Moreland LW, Emery P (eds) TNF inhibition in the treatment of rheumatoid arthritis. Martin Dunitz, London, 71-93

van de Putte LB, Atkins C, Malaise M, et al. (2004) Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 63:508-516

Wallace KL, Langley R, Bissonnette R, Melluli L, Hoffman R (2005a) Quality of life in patients with psoriatic arthritis treated with adalimumab: subanalysis of studies in moderate to severe psoriasis [abstract]. J Am Acad Dermatol 52(3 Suppl):192 (poster P2783) Wallace KL, Gordon KB, LangleyM, et al. (2005b) Dermatolog-ic quality of life in patients with moderate to severe plaque psoriasis receiving 48 weeks of adalimumab therapy [abstract]. J Am Acad Dermatol 52(3 Suppl):180 (poster P2734)

Wallace KL, Bissonnette R, Leonardi C, et al. (2005c) Effects of adalimumab on health status as measured by EQ-5D in patients with moderate to severe plaque psoriasis [abstract]. J Am Acad Dermatol 52(3 Suppl):181 (poster P2741) Wallace KL, Leonardi C, Kempers S, et al. (2005d) General physical and mental health status in patients with moderate to severe plaque psoriasis receiving 48 weeks of adalimumab therapy [abstract]. J Am Acad Dermatol 52(3 Suppl):185 (poster P2757)

Weinblatt ME, Keystone EC, Furst DE, et al. (2003) Adalimumab, a fully human anti-tumor necrosis factor a monoclonal antibody for the treatment of RA in patients taking concomitant methotrexate. The ARMADA trial. Arthritis Rheum 48:35-45 Weinblatt ME, Keystone EC, Furst DE, et al. (2004) The ARMADA trial: sustained efficacy and long-term safety of adalimumab (Humira) plus methotrexate over 3 years in patients with long-standing rheumatoid arthritis [abstract]. Ann Rheum Dis 64(Suppl 1):295 (poster FRI0152) Weinblatt ME, Keystone EC, Furst DE, et al. (2005) Long-term efficacy, remission, and safety of adalimumab (HUMIRA®) plus methotrexate in patients with rheumatoid arthritis in the ARMADA trial [abstract]. Arthritis Rheum 52(Suppl): S563 (poster 1497) Wells AF, Kupper H, Fischkoff S, Chartash E (2003) Injection site reactions in adalimumab rheumatoid arthritis (RA) pivotal clinical trials [abstract]. Ann Rheum Dis 62(Suppl I): 411 (abstract AB0166) Williams RO, Feldmann M, Miani RN (1992) Anti-tumour necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 89:974-978 Zhou H, Buckwalter M, Boni J, et al. (2004) Population-based pharmacokinetics of the soluble TNFr etanercept: a clinical study in 43 patients with ankylosing spondylitis compared with post hoc data from patients with rheumatoid arthritis. Int J Clin Pharmacol Ther 42:267-276

Was this article helpful?

0 0
Osteoarthritis

Osteoarthritis

Thank you for deciding to learn more about the disorder, Osteoarthritis. Inside these pages, you will learn what it is, who is most at risk for developing it, what causes it, and some treatment plans to help those that do have it feel better. While there is no definitive “cure” for Osteoarthritis, there are ways in which individuals can improve their quality of life and change the discomfort level to one that can be tolerated on a daily basis.

Get My Free Ebook


Post a comment